CK7 and consensus molecular subtypes as major prognosticators in ^V600EBRAF mutated metastatic colorectal cancer.

ABSTRACT:

Background

^V600EBRAF mutated metastatic colorectal cancer (mCRC) is a subtype (10%) with overall poor prognosis, but the clinical experience suggests a great heterogeneity in survival. It is still unexplored the real distribution of traditional and innovative biomarkers among ^V600EBRAF mutated mCRC and which is their role in the improvement of clinical prediction of survival outcomes.

Methods

Data and tissue specimens from 155 ^V600EBRAF mutated mCRC patients treated at eight Italian Units of Oncology were collected. Specimens were analysed by means of immunohistochemistry profiling performed on tissue microarrays. Primary endpoint was overall survival (OS).

Results

CDX2 loss conferred worse OS (HR = 1.72, 95%CI 1.03-2.86, p = 0.036), a

SUBMITTER: Loupakis F 

PROVIDER: S-EPMC6889398 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature